11.79
前日終値:
$11.89
開ける:
$11.95
24時間の取引高:
264.11K
Relative Volume:
0.30
時価総額:
$1.06B
収益:
-
当期純損益:
$-56.88M
株価収益率:
-17.85
EPS:
-0.6604
ネットキャッシュフロー:
$-39.43M
1週間 パフォーマンス:
-5.68%
1か月 パフォーマンス:
-6.28%
6か月 パフォーマンス:
+69.88%
1年 パフォーマンス:
+284.04%
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
DRTS
Alpha Tau Medical Ltd
|
11.79 | 1.10B | 0 | -56.88M | -39.43M | -0.6604 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-12-15 | 開始されました | Citigroup | Buy |
| 2023-04-24 | 開始されました | H.C. Wainwright | Buy |
| 2022-04-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-04-08 | 開始されました | Piper Sandler | Overweight |
| 2022-04-04 | 開始されました | Citigroup | Buy |
すべてを表示
Alpha Tau Medical Ltd (DRTS) 最新ニュース
DRTS|Alpha Tau Medical Ltd|Price:12.200|Chg%:-0.300 - TradingKey
Alpha Tau Medical Ltd (DRTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alpha Tau Medical (DRTS) Clinical Win Puts Its Pricey Valuation Back In Focus - simplywall.st
Alpha Tau Medical Ltd (DRTS) Cash Flow - TradingKey
DRTS|Alpha Tau Medical Ltd|Price:12.690| - TradingKey
Alpha Tau Medical Ltd (DRTS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
DRTS Stock Gets A Pre-Market Boost – Retail Shrug Off Wider Q1 Loss Ahead Of Key Pancreatic Cancer Data Reveal This Week - Stocktwits
Alpha Tau Medical (DRTS) Is Down 7.7% After Reporting 100% Response In Alpha DaRT Combo Study - simplywall.st
Enterprise value to EBIT forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
DRTS|Alpha Tau Medical Ltd|Price:12.500|Chg%:-0.740 - TradingKey
Alpha Tau Medical Ltd. Revenue Breakdown – NASDAQ:DRTS - TradingView
Enterprise value to EBITDA forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
Enterprise value to revenue forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
H.C. Wainwright reiterates Alpha Tau Medical stock rating at buy - Investing.com
H.C. Wainwright reiterates Alpha Tau Medical stock rating at buy By Investing.com - Investing.com UK
Alpha Tau Medical Ltd. (DRTS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alpha Tau Medical's (DRTS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Alpha Tau Medical Ltd. (DRTS) stock price, news, quote and history - Yahoo Finance UK
H.C. Wainwright Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
DRTS Stock Price, Quote & Chart - ChartMill
Alpha Tau reports positive trial results for cancer therapy combo By Investing.com - Investing.com Nigeria
Alpha Tau rises on Alpha DaRT head and neck cancer data - Seeking Alpha
Alpha Tau Posts Strong Alpha DaRT–Keytruda Data in Head and Neck Cancer Study - TipRanks
Alpha Tau reports positive trial results for cancer therapy combo - Investing.com
100% cancer response in Alpha DaRT trial for Alpha Tau Medical (Nasdaq: DRTS) - Stock Titan
All 9 Evaluable Patients Responded in Alpha Tau Cancer Trial - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Alpha Tau Medical (DRTS) Reaches ADMIRE Milestone, Is The Stock Now Fully Valued? - simplywall.st
H.C. Wainwright reiterates Alpha Tau Medical stock rating on immunocompromised patient treatment By Investing.com - Investing.com South Africa
Alpha Tau Medical (DRTS) Is Up 6.6% After First Immunocompromised cSCC Patient Treated With Alpha DaRT - simplywall.st
H.C. Wainwright reiterates Alpha Tau Medical stock rating on immunocompromised patient treatment - Investing.com Nigeria
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
DRTS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15 - GuruFocus
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center - The Manila Times
Alpha Tau Medical (Nasdaq: DRTS) treats first ADMIRE trial patient with Alpha DaRT - Stock Titan
Alpha Tau Successfully Treats First Immunocompromised - GlobeNewswire
Barclays Sticks to Its Buy Rating for Alpha Tau Medical Ltd (DRTS) - The Globe and Mail
Barclays Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Top Executive Makes Bold Move in Alpha Tau Medical’s Latest Insider Trade - TipRanks
Alpha Tau Medical stock tracks a thin session. Investors watch its listing and filings. - ad-hoc-news.de
Alpha Tau Medical: Alpha Particles Are Still Interesting, But Beware The Hype (NASDAQ:DRTS) - Seeking Alpha
Alpha Tau Medical (DRTS) CFO trades 2,270 shares in exercise and sale - Stock Titan
Enterprise value to revenue forward of Alpha Tau Medical Ltd. – NASDAQ:DRTS - TradingView
Price to sales forward of Alpha Tau Medical Ltd. – BOATS:DRTS - TradingView
Price to earnings forward of Alpha Tau Medical Ltd. – NASDAQ:DRTS - TradingView
Major Insider Move at Alpha Tau Medical Shakes Up Investor Buzz - TipRanks
Enterprise value to EBIT forward of Alpha Tau Medical Ltd. – NASDAQ:DRTS - TradingView
Insider Sell: Raphi Levy Sells Shares of Alpha Tau Medical Ltd (DRTS) - GuruFocus
Enterprise value to EBITDA forward of Alpha Tau Medical Ltd. – BOATS:DRTS - TradingView
Alpha Tau Medical (DRTS) Is Up 17.9% After First International Alpha DaRT Glioblastoma Procedure – Has The Bull Case Changed? - simplywall.st
Form 144 Alpha Tau Medical Ltd. For: 6 July By Investing.com - Investing.com Nigeria
Alpha Tau Medical Ltd (DRTS) 財務データ
収益
当期純利益
現金流量
EPS
Alpha Tau Medical Ltd (DRTS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Levy Raphi | Chief Financial Officer |
Jul 06 '26 |
Sale |
14.00 |
2,270 |
31,782 |
90,180 |
大文字化:
|
ボリューム (24 時間):